The β-catenin gene is frequently mutated in patients with hepatocellular carcinoma (HCC) and has long been thought to be one of the major oncogenes involved in the hepatocarcinogenesis. The prognostic role of βcatenin mutation in HCC remains unclear. To address this issue,
a search for relevant studies was performed in the PubMed, Embase and Web of Science databases. The pooled effect was calculated from the available data to evaluate the correlation of βcatenin mutation with overall survival rate and tumor clinicopathological features in patients with
HCC. The pooled odds ratio (OR) was calculated using the MantelHaenszel model for fixed effects. Three studies met the inclusion criteria. A total of 618 cases were included, and βcatenin mutation was identified in 104 of them. The metaanalysis revealed that the presence of βcatenin
mutation (n=104), compared with the control group (n=514), was correlated with a longer overall survival rate [OR, 0.33; 95% confidence interval (CI), 0.210.53; P<0.00001] in patients with HCC. No significant heterogeneity was found among the eligible studies (I2=0%; P=0.72).
βcatenin mutation was correlated with a relatively lower rate of hepatitis B virus infection (OR, 0.36; 95% CI, 0.210.61; P=0.0002), improved tumor differentiation (OR, 0.32; 95% CI, 0.190.56; P<0.0001) and a lower tumornodemetastasis stage (I+II)
(OR, 0.23; 95% CI, 0.140.38; P<0.00001). These findings suggest that βcatenin mutation may predict a favorable prognosis in patients with HCC.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Institute of Biomedical Sciences, Fudan University, Shanghai 200032, P.R. China
Publication date: January 1, 2015
More about this publication?